<SEC-DOCUMENT>0001437749-22-026900.txt : 20221110
<SEC-HEADER>0001437749-22-026900.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110161135
ACCESSION NUMBER:		0001437749-22-026900
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		221377265

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20221107_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:mbrx="http://www.mbrx.com/20221110"><head>
	<title>mbrx20221107_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 11/7/2022 7:50:13 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20228K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20228K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20221110.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20228K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2022-11-10</xbrli:startDate>
<xbrli:endDate>2022-11-10</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20228K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20228K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>November 10, 2022</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="text-align: center;"><img alt="pic1.jpg" src="pic1.jpg" /></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-transform:uppercase;">Delaware</span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 34%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align: middle; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">or Organization)</div>
			</td>
			<td style="vertical-align: top; width: 34%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressAddressLine2"><b>Suite 950</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20228K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d20228K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20228K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0; Emerging growth company&#xa0;<ix:nonNumeric contextRef="d20228K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#xa0;&#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20228K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.02</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On November 10, 2022, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended September 30, 2022 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01 </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;text-indent:21pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 5%;">
			<div style="margin: 0pt;"><b>Exhibit</b></div>

			<div style="margin: 0pt;"><b>No.</b></div>
			</td>
			<td style="vertical-align: top; width: 95%;"><b>Description</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">&#xa0;</td>
			<td style="vertical-align: top; width: 95%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_443670.htm" style="-sec-extract:exhibit;">Press Release dated November 10, 2022</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">&#xa0;</td>
			<td style="vertical-align: top; width: 95%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">104</td>
			<td style="vertical-align: top; width: 95%;">Cover page Interactive Data File (embedded within the Inline XBRL document)</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:36pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></div>
			</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 27%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 27%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 3%;">Date:&#xa0; November 10, 2022</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 3%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 27%;">&#xa0;</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 3%;">By: &#xa0;<span style="text-decoration: underline;">/s/ Jonathan P. Foster</span>&#xa0;</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">Jonathan P. Foster</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#xa0;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">Chief Financial Officer</td>
			<td style="vertical-align: middle; width: 20%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">2</div>
</div>
</div>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_443670.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_443670.htm</title>
	<!-- Generated by ThunderDome Portal - 11/10/2022 5:26:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;"><img alt="pic1.jpg" src="pic1.jpg"></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Continued execution across clinical and preclinical development programs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Three Phase 1b/2 clinical studies with enrollment or dosing now underway </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Sufficient capital to fund operations beyond mid-2024</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>&#8211; Company to host conference call and webcast today at 5:00 PM ET</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>HOUSTON, November 10, 2022 /PRNewswire/ -- Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (&#8220;Moleculin&#8221; or the &#8220;Company&#8221;), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update. As previously announced, the Company will host its inaugural quarterly conference call and live audio webcast, today, November 10, 2022, at 5:00 PM ET (details below).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;We have made fundamental progress across our pipeline this past quarter. Of note, we have three active Phase 1/2 clinical trials for Annamycin and patients treated thus far continue to demonstrate no evidence of cardiotoxicity. Additionally, we have gained valuable insight in all of our ongoing development programs and are well-positioned to successfully execute operationally through the remainder of the year. Looking ahead, as we continue delivering on our initiatives, I believe the fourth quarter is poised to be an exciting conclusion of a transformational year and foundational for what is to come,&#8221; commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Highlights </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Opened enrollment in the Phase 1/2 Study of Annamycin in combination with cytarabine for the treatment of Acute Myeloid Leukemia (&#8220;AML&#8221;) in Europe.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Initiated and began dosing in the Phase 2 portion of the U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases ("STS lung mets").</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">An investigator-funded, second Phase 1b/2 clinical trial of Annamycin in STS lung mets in Europe was commenced and began dosing.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Continued expanding the safety profile of Annamycin with a third report from an independent cardiology expert assessing recent subjects. This assessment again confirmed that there was no evidence of cardiotoxicity associated with Annamycin. This brings the total to 42 subjects where no evidence of cardiotoxicity has been identified by an independent expert cardiologist.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Enrolled what is expected to be the final subject in the Phase 1 portion of a clinical trial of WP1066 being conducted in collaboration with Emory University for the treatment of pediatric brain tumors, including medulloblastoma and diffuse interstitial pontine glioma (&#8220;DIPG&#8221;).</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Concluded Phase 1a first-in-human clinical trial of WP1122 for the treatment of COVID-19 in the United Kingdom establishing a safe and tolerable dose in healthy volunteers.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Announced the selection of WP1096 (a compound in the WP1122 portfolio) as novel potential antiviral, by the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), part of the National Institutes of Health (&#8220;NIH&#8221;), for NIH-funded animal studies.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Received U.S. Food and Drug Administration (&#8220;FDA&#8221;) Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme (&#8220;GBM&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pipeline Update </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Next Generation Anthracycline </b>&#8211;<b> Annamycin</b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annamycin is the Company's next-generation anthracycline that has been designed to be non-cardiotoxic and has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin (a commonly prescribed anthracycline), as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory AML and STS lung metastases and the Company believes it may have the potential to treat additional indications.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>STS Lung Mets</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recently initiated its Phase 2 portion of the U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of STS lung mets (&#8220;MB-107&#8221;) and has begun enrollment and dosing.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the Phase 1b portion of the study, 15 subjects were enrolled and treated per the protocol in four cohorts to determine the maximum tolerable dose and/or the RP2D. Each cohort had three subjects, except for the fourth cohort, which (per the protocol) was expanded to six subjects after a dose-limiting toxicity (DLT) occurred in a single subject. The Company concluded the Phase 1b portion after the fourth cohort of 390 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> was documented to be safe. Based on findings from the Phase 1b position of the trial, 360 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> demonstrated it may be tolerated by subjects initially, however continued treatment was deemed at risk to be delayed or interrupted due to adverse events (primarily myelosuppression, which is anticipated with high doses of anthracycline therapy), hence lowering the dose from 360 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> to 330 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> was contemplated in advance of beginning the Phase 2 expansion pending results from the first three subjects in the expansion phase. Adverse Events, primarily myelosuppression, in the first three subjects at 360 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> led the Company to lower the RP2D to 330 mg/m<sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup> in October 2022, which the Company believes will enable continued treatment of subjects with fewer interruptions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company expects to treat at least 25 subjects in this Phase 2 portion of the clinical trial. For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung mets, please visit clinicaltrials.gov and reference identifier NCT04887298.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, the investigator-funded, second Phase 1/2b clinical trial of Annamycin for the treatment of STS lung mets was recently initiated. The grant-funded clinical trial is being led by Prof. Piotr Rutkowski, MD, PhD, Head of Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. The trial will use a dosing regimen of once weekly for three weeks in a 28-day cycle rather than once every 21 days as in the US trial. Two subjects have been dosed to date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>AML </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Patient enrollment and screening has been initiated in the Company&#8217;s Phase 1/2 clinical trial in Poland evaluating Annamycin in combination with Cytarabine (also known as &#8220;Ara-C&#8221; and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with AML who are refractory to or relapsed after induction therapy (&#8220;MB-106"). Ongoing efforts to open additional clinical sites in Poland and other European countries for the MB-106 clinical trial are underway.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of STS lung metastases, in addition to Orphan Drug and Fast Track Designation for the treatment of relapsed or refractory AML.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Q4 2022: Commence dosing and open additional clinical sites in Poland and other European countries in the Phase 1/2 study of Annamycin in combination with Ara-C in Acute Myeloid Leukemia.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Q1 2023: Report Phase 2 interim data from ongoing Phase 1b/2 study of Annamycin for the treatment of STS lung mets in the US and Europe.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Flagship Immune/Transcription Modulator </b>&#8211;<b> WP1066</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">WP1066 is designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (Tregs) while also inhibiting key oncogenic transcription factors, including p-STAT3 (phosphorylated signal transducer and activator of transcription 3), c-Myc (a cellular signal transducer named after a homologous avian virus called Myelocytomatosis) and HIF-1&#945; (hypoxia inducible factor 1&#945;). These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation, and the angiogenesis (coopting vasculature for blood supply), invasion, metastasis and inflammation associated with tumors. They may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Moleculin is in ongoing discussions with multiple academic institutions in separate programs evaluating WP1066 for the treatment of brain tumors. The Company expects the investigator-sponsored clinical trials or programs for the treatment of adult and pediatric brain tumor to commence in the first half of 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, WP1066 is currently being evaluated in collaboration with Emory University for the treatment of pediatric brain tumors, including medulloblastoma and DIPG. In October 2022, the Emory trial enrolled the last subject in the last cohort at 8 mg/kg. Discussions are underway to explore WP1066 in combination with radiation on similar tumors in a Phase 2 clinical trial in the near future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In April 2022, the Company received IND clearance from the FDA to conduct a Phase 1 study of WP1066 for the treatment of recurrent malignant glioma. Since that time, the Company has been evaluating strategic partnerships and collaborations to utilize this IND. WP1066 has received Orphan Drug Designation for the treatment of brain tumors, as well as Rare Pediatric Disease designation for three other pediatric indications. Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme (GBM).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">H1 2023: Commencement of investigator-sponsored clinical trials or programs for the treatment of adult and pediatric brain tumors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Metabolism/Glycosylation Inhibitor </b>&#8211;<b> WP1122 Portfolio</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells. WP1122 has also been shown to have a greater antiviral effect than 2-DG against SARS-CoV-2 in MRC-5 cells in culture. The improved pharmacokinetic and pharmacodynamic (PK/PD) profile of WP1122 compared to 2-DG was noted in mice following oral dosing at equimolar (i.e., equivalent levels of 2-DG) doses. The WP1122 Portfolio includes numerous analogs, including WP1096, which has demonstrated the potential for broad antiviral capabilities in a wide range of in vitro models including multiple arenaviruses, Zika virus, and HIV.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Glioblastoma Multiforme</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In September of 2022, Moleculin was granted Orphan Drug Designation of WP1122 for the treatment of GBM from the FDA. Additionally, based on preclinical data indicating the potential for WP1122 as a treatment for GBM, Moleculin received FDA clearance of its Investigational New Drug application to initiate a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM. The Company is currently evaluating opportunities for collaboration in clinical development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>COVID-19 </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In October 2022, the Company concluded its Phase 1a, first-in-human, randomized, double-blind, placebo-controlled, overlapping SAD and MAD clinical trial investigating the effects of WP1122 administered as an oral solution in healthy human volunteers. A safe and tolerable dose was established for WP1122 in this trial, which now provides a starting point for a range of potential Phase 2 clinical trials. Approximately 80 subjects were enrolled in the trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Upcoming Milestones Expectations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Identify investigators interested in initiating a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Report preliminary findings of NIH-funded animal testing of WP1096 in the Tacaribe Arenavirus by the end of the first quarter 2023.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Financial Results for the Third Quarter 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development (R&amp;D) expense was $14.8 million and $11.2 million for the nine months ended September 30, 2022 and 2021, respectively. The increase of $3.6 million is mainly related to increased clinical trial activity as described above, a license termination fee, and costs related to manufacturing of additional drug product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">General and administrative expense was $8.7 million and $6.4 million for the nine months ended September 30, 2022 and 2021, respectively. The increase of $2.3 million is mainly related to an increase in regulatory and legal services, consulting and advisory fees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For the nine months ended September 30, 2022 and 2021, the Company incurred net losses of $22.3 million and $13.1 million, respectively, and had net cash flows used in operating activities of $20.4 million and $14.7 million, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company ended the quarter with $50.4 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&amp;D rate of expenditures, beyond mid-2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Conference Call and Webcast</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Moleculin management will host its inaugural quarterly conference call and live audio webcast for investors, analysts, and other interested parties today, Thursday, November 10, 2022, at 5:00 PM ET.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>About Moleculin Biotech, Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company&#8217;s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements </b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company's ability to meet the milestones described in this release under the sections &#8220;Upcoming Milestones Expectations&#8221;, the Company's forecasted cash burn rate (including its estimate of cash sufficient to meet its projected operating requirements), the ability of the US STS lung metastases clinical trial to continue the recruitment of subjects, the ability of the EU STS lung metastases trial to recruit subjects, the ability of Annamycin to eventually be approved by the FDA and the European Medicines Agency, and the ability of the Company to attract collaborators for expanded development of the WP1122 portfolio and the WP1066 portfolio for the treatment of adult and pediatric brain tumors. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including &#8216;believes,&#8217; &#8216;estimates,&#8217; &#8216;anticipates,&#8217; &#8216;expects,&#8217; &#8216;plans,&#8217; &#8216;projects,&#8217; &#8216;intends,&#8217; &#8216;potential,&#8217; &#8216;may,&#8217; &#8216;could,&#8217; &#8216;might,&#8217; &#8216;will,&#8217; &#8216;should,&#8217; &#8216;approximately&#8217; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. &#8220;Risk Factors&#8221; in our most recently filed Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact:</b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">JTC Team, LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jenene Thomas</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(833) 475-8247</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>MBRX@jtcir.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="margin: 0pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt;"><b>Moleculin Biotech, Inc. </b></p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="margin: 0pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt;"><b>Unaudited Condensed Consolidated Balance Sheets</b></p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%; border-bottom: 1px solid black; border-top: 1px solid black;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>September 30,</b></b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid black; border-top: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50,392</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70,903</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,101</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,594</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">53,493</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,497</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">306</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">338</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,148</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,148</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease right-of-use asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">425</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65,372</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84,090</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts payable, accrued expenses and other current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,362</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,622</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,362</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,622</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liability - long-term, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">365</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">63</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant liability - long term</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">228</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,412</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,955</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,097</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58,417</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">78,993</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65,372</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84,090</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="margin: 0pt; line-height: 1.25; font-family: Times New Roman; font-size: 10pt;"><b>Unaudited Condensed Consolidated Statements of Operations </b></p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;">&nbsp;</td>
			<td colspan="6" id=".amt.D5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine Months Ended</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30,</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands, except share and per share amounts)</b></p>
			</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenues</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,965</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,095</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,790</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,239</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative and depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,119</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,062</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,802</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,524</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total operating expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,084</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,157</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,592</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,763</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,084</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,157</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(23,592</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,763</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain from change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,678</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,184</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,428</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest income, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">87</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">236</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(8,611</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(4,379</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(22,255</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(13,069</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
			<td id=".lead.B5">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss per common share - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.30</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.15</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.78</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.50</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding - basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,627,610</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,573,476</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,596,501</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,302,638</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20221110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2022 9:32:57 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:mbrx="http://www.mbrx.com/20221110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20221110">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20221110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20221110_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20221110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20221110/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20221110_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2022 9:32:57 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20221110/role/statement-document-and-entity-information" xlink:href="mbrx-20221110.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20221110/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20221110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2022 9:32:57 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20221110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 11/9/2022 9:32:57 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20221110/role/statement-document-and-entity-information" xlink:href="mbrx-20221110.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20221110/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pic1.jpg
<TEXT>
begin 644 pic1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !A 20# 2(  A$! Q$!_\0
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MWT/"OVROVTE_9)GT%&\/G6_[;69LB[\CR?+*#^XV<[_TKQ$?\%F8S_S(3?\
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M"8G#1Q%&JZ<G!RE"TZ;O"2E'72[36SOY'!C,$Z[C.,N62NK[Z/?<_)[]GO\
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M*FA^*_VKOBQX,&O:+?1G1? &FZW!;6&GW:N C2H),R3%@/E!8\X+$?(/IO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140112750221024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Nov. 10,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>mbrx20221107_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20221110.xsd" xlink:type="simple"/>
    <context id="d20228K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20228K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20228K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20228K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20228K">2022-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20228K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20228K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20228K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20228K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20228K">5300 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20228K">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20228K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20228K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20228K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20228K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20228K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20228K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20228K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20228K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20228K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20228K">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="d20228K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20228K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20228K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M<(%J531-PLM<!   .Q$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RE
MF&UOZC84Q[^*E4G3)K7- T^E R1*N;?HMI05[NZT:2],8L!J8F>V4\JWWW&
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MOU/?7QB9YKOCI32PU\Y/-XR"+=@&\'PEI3E>V UW\7_)X!]02P,$%     @
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MX-R#8._AE8P=S8\?=_<#4$L#!!0    ( '"!:E4D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !P@6I599!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ <(%J5260\ECM    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ <(%J59E<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !P@6I5-$W"RUP$   [$0  &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ <(%J59^@&_"Q
M @  X@P   T              ( !G@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " !P@6I5EXJ[',     3 @  "P              @ %Z#P  7W)E;',O
M+G)E;'-02P$"% ,4    " !P@6I5.JJBYT !   \ @  #P
M@ %C$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ <(%J520>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ <(%J5660>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20221107_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20221110/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20221107_8k.htm">mbrx20221107_8k.htm</File>
    <File>ex_443670.htm</File>
    <File>mbrx-20221110.xsd</File>
    <File>mbrx-20221110_def.xml</File>
    <File>mbrx-20221110_lab.xml</File>
    <File>mbrx-20221110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pic1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20221107_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20221110_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20221107_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20221110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20221110_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20221110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20221110",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20221107_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20221110/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20221107_8k.htm",
      "contextRef": "d20228K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity, Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mbrx.com/20221110/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-22-026900-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-026900-xbrl.zip
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M@<,Q,&&C$?^ "(<Q ">'@ER;N)_ ]WA([@=:$RC5+.&"G(_1^8&.F4"60WZ
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MD+:2<"1R10O@XP.VS>E,!0.7FOD4HZ:G*CN,[)@G@7(1\2XVG5+']I,=<L=
M8P)?^Z(#G]<>BE$*\((U!DHD[ V(7:^]+O6?1.S2CH3T,)5H_7)]?GV9G0,%
M/(RUQSO<<(0?_4ZLGFO@]^QUW&3P0'DHT+GM9D?'U8[XB7<$!IO!C+!D'.6C
M[TL_\Q)/#<\M%X0V':+@)M&<]?'R/ W>?0V#/DAW^OJEB*!QGMM08^7[)]A&
MJ=5QDS@P&!BR2+OX].'F-7;%.D?[2UB@1<?ZYS6M+\!M&GZ(#''NQ?V0FP.3
MYHJ35% $^&[FYHV=_-MP@HO%.HT\1\W%>:+\*?:OH$+PU5Y&(EX@$?G-J:]J
MT=Y*O0W/]VHYMY:V;/K=J.\_4UA)B7G7MX1#9V[<-!,W<9#-E&[#J%.$I]U)
M@%]H-VJ@XJ1V=/!(DQ $_G<_3#HV3D*J1]?W'(PQB,@,[0XIE-S0=]1))!Z\
M1[F#6!VBX!W;0:<%!_2$QP/XT$4A0%@%C4< Y]T5)D@7.W(C%488!"@VH6_'
M=FT**S"!IX#0=7FD2!(?XPZ(# U![DP8<51GA77*WK"]PM'N2&$6"H<'>%0*
M'X:B"ZW&Z)Z=WWRF0>2#>SJ.3,9J#M*@3F(C!I-R^4"?D(N<@0'4HEX93X^K
M,6 !<R=$T\2#SWG@ Y:"S['/D)J?D9HW(IX*^]N4>3_D6$4&X(@U]8D)PF#F
M?3I2#%&G<*8/M6;C,+4&,C'42[S\,2,%%G)!Z^6(]\FMS?(L*Q_YZ937!,WN
M@<&:^[FX)88MA0XQD710X)9 R,4(0A#UIH][GK :((;[A#XFK$LL0E<J#83J
M?+?=Q"T[P]#HKEK8N]O699U=<;.O6H%%LQ0@1P_)0+R'"#*1IP B\@6#/?=M
M>'V[/+P="O+*D+1"NMC?LWGR+H([.(VH1C*<E((.S6Y??G[88;Y)\I?\+W#N
MX1M..BZ, V=[P4S##B/I+7L;&CRN0_NXP=S>KGL:)<$$JQR50ZTO$(7QOMG2
M3@PQ"2+V6Z>[\/X9S=GR0;=*#(O4T1B5J+,/G#2#A\%!BX+7%'$OC5="@S2#
MT-XT6/M@EF/, :(LK68P;DE<HC)$TG62LH7P4&!,@&;*P%563B[0O(7 ,#\H
MIM".'M7<P>#@ ZD1*8X8)@%V84EL%K<P;@D,_T0XKNT@!#LEA!W*7 0,P'!1
M42/ 2/,9'C% ]Z8=9&<#"%\D1B+OMVP\P:2" 5@B?3H%<& 2H;8_:#O0*LR6
MPF@_M6?-5I12XP8.5]%@H!U7YQH@96W/T[/2"H#V'H&S\"A#'MDHE*9F/ K-
ME?:[-@ASKV.#B(Z3BW5%BV6P28NEVAC9/C#(;,GMB*(-!>2G94Y%W.P7!.;W
M%8R[CDKST-PYTI(CE*KP2 "/VCN(.$C%/_)S5^#@T^TRU:B;L2-HV4]@'? H
M^FWK]M.'/TH1'$8A'*7\:H[HQDH#JB>42D6/,/6JT-;'A[NTL5$)*;D.2N_V
MN[70?QY^B+$F=OOIR[>;; [P#<PSR_]X=]H/=<>WYY^N:A_NKL[_J)U_?+BZ
M>\^X\\P'T8F*::%^]T1A,"=,,01K!=\1HNA@>MG?&_0_>(^;C[T0XX2UXD=#
M!/C]<C0!D(IOGO[#UXO/MO<XD0 I'49;0Z_-4)M@^^!45L VEF=R4<Y7BF%H
MB$-N[9<DG3W69"Z:R!@3"\&%#M%E3D&NX,/Z25S0XF!<DV'W5IL:)"L.5; G
M&ZR!=!02!EWO^4]D%H)_J8#MZ>EUR+Y</#3VCHX.6\='ZXA_G1I"*>"SD8HO
M0-WLMCH343<O<')0_0Y[6]("[84<YRS#Z:5^$*= Q[B.M*IN0[\+3ICMQR&[
M2^)'_SEZM UV<VG 8.$_OPNPOJ'W2X%1_G0L"$=[(#C:[@>03>Q>8=*0#6[
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M+L]L'7=X>3NG)1PV=P,/AWR&$U.RW*PF-TI%,0S4"Q:X9_^#[JKE)V"8U#K
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M\_TEL_E^Q>8CN.H+7J^]]ES^9M[Z82Y_N5.YKN[B\!T6>*VB">O$HCY7E8?
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M6:*RO,"_KV0^E@V6+=BUZ[Z ;1U?G:./Z^L#[SZL8V(] D\PHWW;:[5M"VC
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M+.TQT/+R\R[!;"2N?5\8S/A8U#4)Z,*X_BR,/F@!JLWH:@6Z$D>9.EK*U[
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MHT\C-KMLF]CN+7T>[9&]"V^P>M"?L^88 %+_Z%^A&,B=TCJT;^ : "[LZK;
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M 0 -              "  0    !E>%\T-#,V-S N:'1M4$L! A0#%     @
M<(%J5:5>BWMZ P  +PX  !$              ( !\"<  &UB<G@M,C R,C$Q
M,3 N>'-D4$L! A0#%     @ <(%J55J+@H[L!   UBX  !4
M ( !F2L  &UB<G@M,C R,C$Q,3!?9&5F+GAM;%!+ 0(4 Q0    ( '"!:E5S
M]WC0$08  -<^   5              "  ;@P  !M8G)X+3(P,C(Q,3$P7VQA
M8BYX;6Q02P$"% ,4    " !P@6I5_@ 5/H<$  "A+P  %0
M@ '\-@  ;6)R>"TR,#(R,3$Q,%]P<F4N>&UL4$L! A0#%     @ <(%J52H'
M/-: #@  !E<  !,              ( !MCL  &UB<G@R,#(R,3$P-U\X:RYH
M=&U02P$"% ,4    " !P@6I5[SP N7$D  !S)@  "               @ %G
A2@  <&EC,2YJ<&=02P4&      < !P"Z 0  _FX

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
